Original Article

You have full text access to this OnlineOpen article

Parathyroid hormone (PTH)–induced bone gain is blunted in SOST overexpressing and deficient mice

  1. Ina Kramer1,
  2. Gabriela G Loots2,3,
  3. Anne Studer1,
  4. Hansjoerg Keller1,
  5. Michaela Kneissel1,*

Article first published online: 14 DEC 2009

DOI: 10.1359/jbmr.090730

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 2, pages 178–189, February 2010

Additional Information

How to Cite

Kramer, I., Loots, G. G., Studer, A., Keller, H. and Kneissel, M. (2010), Parathyroid hormone (PTH)–induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res, 25: 178–189. doi: 10.1359/jbmr.090730

Author Information

  1. 1

    Musculoskeletal Disease Area, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland

  2. 2

    Biology and Biotechnology Division, Lawrence Livermore National Laboratory, 7000 East Avenue, L-452 Livermore, CA, USA

  3. 3

    Department of Molecular and Cell Biology, Division of Genetics, Genomics, and Development, and Center for Integrative Genomics, University of California–Berkeley, Berkeley, CA, USA

*Musculoskeletal Disease Area, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

Publication History

  1. Issue published online: 19 FEB 2010
  2. Article first published online: 14 DEC 2009
  3. Manuscript Accepted: 8 JUL 2009
  4. Manuscript Revised: 7 MAY 2009
  5. Manuscript Received: 16 JAN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (498K)

References

  • 1
    Bonnick SL. Osteoporosis in men and women. Clin Cornerstone. 2006; 8: 28–39.
  • 2
    Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005; 26: 688–703.
  • 3
    Khosla S, Westendorf JJ, Oursler MJ. Building bone to reverse osteoporosis and repair fractures. J Clin Invest. 2008; 118: 421–428.
  • 4
    Juppner H, Abou-Samra AB, Freeman M, et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science. 1991; 254: 1024–1026.
  • 5
    Nishida S, Yamaguchi A, Tanizawa T, et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone. 1994; 15: 717–723.
  • 6
    Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA, McCauley LK. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone. 2008; 42: 806–818.
  • 7
    Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 1995; 136: 3632–3638.
  • 8
    Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999; 104: 439–446.
  • 9
    Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts: a putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003; 278: 50259–50272.
  • 10
    Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007; 40: 1434–1446.
  • 11
    Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005; 37: 148–158.
  • 12
    Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146: 4577–4583.
  • 13
    O'Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE. 2008; 3: e2942.
  • 14
    Bonewald LF. Osteocytes as dynamic multifunctional cells. Ann NY Acad Sci. 2007; 1116: 281–290.
  • 15
    Fermor B, Skerry TM. PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. J Bone Miner Res. 1995; 10: 1935–1943 .
  • 16
    Langub MC, Monier-Faugere MC, Qi Q, Geng Z, Koszewski NJ, Malluche HH. Parathyroid hormone/parathyroid hormone-related peptide type 1 receptor in human bone. J Bone Miner Res. 2001; 16: 448–456.
  • 17
    van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 2005; 16: 319–327.
  • 18
    Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 19: 1842–1844.
  • 19
    Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22: 6267–6276.
  • 20
    Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005; 15: 928–935.
  • 21
    Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23: 860–869.
  • 22
    Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10: 537–543.
  • 23
    Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68: 577–589.
  • 24
    Balemans W, Patel N, Ebeling M, et al. Identification of a 52-kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002; 39: 91–97.
  • 25
    Staehling-Hampton K, Proll S, Paeper BW, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002; 110: 144–152.
  • 26
    Kneissel M, Boyde A, Gasser JA. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analogue SDZ PTS 893 or human PTH(1–34). Bone. 2001; 28: 237–250.
  • 27
    Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units: report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595–610.
  • 28
    Marshall VM, Allison J, Templeton T, Foote SJ. Generation of BAC transgenic mice. Methods Mol Biol. 2004; 256: 159–182.
  • 29
    Silvestrini G, Ballanti P, Leopizzi M, et al. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol. 2007; 38: 261–269.
  • 30
    Leupin O, Kramer I, Collette NM, et al. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res. 2007; 22: 1957–1967 .
  • 31
    Zhou H, Iida-Klein A, Lu SS, et al. Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone. 2003; 32: 513–520.
  • 32
    Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res. 2001; 16: 1575–1582.
  • 33
    Sutherland MK, Geoghegan JC, Yu C, et al. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone. 2004; 35: 828–835.
  • 34
    van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007; 22: 19–28.
  • 35
    Beamer WG, Donahue LR, Rosen CJ, Baylink DJ. Genetic variability in adult bone density among inbred strains of mice. Bone. 1996; 18: 397–403.
  • 36
    Poole KE, Reeve J. Parathyroid hormone: a bone anabolic and catabolic agent. Curr Opin Pharmacol. 2005; 5: 612–617.
  • 37
    Potts JT, Gardella TJ., Progress, paradox, and potential: parathyroid hormone research over five decades. Ann NY Acad Sci. 2007; 1117: 196–208.
  • 38
    Li X, Zhang Y, Kang H, Liu W, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280: 19883–19887.
  • 39
    Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005; 280: 26770–26775.
  • 40
    Baron R, Rawadi G. Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007; 148: 2635–2643.
  • 41
    Glass DA 2nd, Karsenty G. In vivo analysis of Wnt signaling in bone. Endocrinology. 2007; 148: 2630–2634.
  • 42
    Johnson ML, Kamel MA. The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol. 2007; 19: 376–382.
  • 43
    Piters E, Boudin E, Van Hul W. Wnt signaling: a win for bone. Arch Biochem Biophys. 2008; 473: 112–116.
  • 44
    Sawakami K, Robling AG, Ai M, et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem. 2006; 281: 23698–23711.
  • 45
    Iwaniec UT, Wronski TJ, Liu J, et al. PTH stimulates bone formation in mice deficient in Lrp5. J Bone Miner Res. 2007; 22: 394–402.
  • 46
    Bodine PV, Seestaller-Wehr L, Kharode YP, Bex FJ, Komm BS. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J Cell Physiol. 2007; 210: 352–357.
  • 47
    Kulkarni NH, Halladay DL, Miles RR, et al. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem. 2005; 95: 1178–1190.
  • 48
    Tobimatsu T, Kaji H, Sowa H, et al. Parathyroid hormone increases β-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology. 2006; 147: 2583–2590.
  • 49
    Suzuki A, Ozono K, Kubota T, Kondou H, Tachikawa K, Michigami T. PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3β in osteoblastic Saos-2 cells. J Cell Biochem. 2008; 104: 304–317.
  • 50
    Wan M, Yang C, Li J, et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev. 2008; 22: 2968–2679.
View Full Article (HTML) Get PDF (498K)